Table 1.
Characteristics of the entire chemotherapy cohort
| Characteristic | Missing (%) | Total (N = 187) |
|---|---|---|
| Age, years | 0 (0.0) | 15.5 [10.4, 18.7] |
| Male, n (%) | 0 (0.0) | 118 (63.1) |
| Height, cm | 1 (0.5) | 163 [135, 175] |
| BMI, kg/m2 | 3 (1.6) | 21.1 [17.0, 25.5] |
| Hypertension, n (%) | 2 (1.1) | 32 (17.1) |
| Diagnosis | ||
| Lymphoma, n (%) | 0 (0.0) | 50 (26.7) |
| Sarcoma, n (%) | 0 (0.0) | 49 (26.2) |
| AML, n (%) | 0 (0.0) | 14 (7.5) |
| ALL, n (%) | 0 (0.0) | 36 (19.3) |
| Blastoma, n (%) | 0 (0.0) | 8 (4.3) |
| Wilms tumor, n (%) | 0 (0.0) | 10 (5.4) |
| Other, n (%) | 0 (0.0) | 20 (10.7) |
| Baseline cardiac medications, n (%) | 0 (0.0) | 0 (0.0) |
| Duration of chemotherapy, years | 3 (1.6) | 0.66 [0.35, 1.92] |
| Cumulative anthracycline exposurea, mg/m2 | 3 (1.6) | 200 [135, 343] |
| Duration of follow-up, years | 0 (0.0) | 2.78 [1.31, 4.21] |
LEGEND Normally distributed variables were presented as mean ± standard deviation while non-normally distributed variables were presented as median (interquartile range). Categorical variables are expressed as frequency (percentage). ABBREVIATIONS: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BMI, body mass index